person · Reporting owner
JOHNSON SABRINA MARTUCCI
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AETHLON MEDICAL INCAEMD · Entity 8580 | Director | March 31, 2022 | March 31, 2022 |
| Atai Beckley N.V.ATAI · Entity 72536 | Director | June 26, 2025 | June 27, 2025 |
| Dare Bioscience, Inc.DARE · Entity 7799 | Director · Chef Executive Officer | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AETHLON MEDICAL INC
Report date March 31, 2022 · Filed March 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,642 |
Reported balance
After 2022-03-31 transaction · row 1
1 source rowRow 1 · 2022-03-31 · Tax withholding · Disposed 2,430 · Balance 33,642 F1: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/21 |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/21
Atai Beckley N.V.
Report date June 26, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 103,000 |
Reported balance
After 2025-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-26 · Grant · Acquired 103,000 · Balance 103,000 F1: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.
Dare Bioscience, Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 | Direct | 10,800 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 10,800 · Balance 10,800 F1: This date is the date on which the reporting person subscribed to purchase the securities. The securities will be issued at a future date when the Issuer accepts the reporting person's subscription. F4: The reported securities are included within 10,800 Investor Units (the Units) purchased by the reporting person in the Regulation A offering of the Issuer for $5 per Unit. Each Unit consists of one share of Preferred Stock, each of which is initially convertible into two shares of Common Stock, and two warrants, each to purchase one share of Common Stock. F2: This security is convertible or exercisable, as applicable, at any time after issuance. F3: The Series A Convertible Preferred Stock (the Preferred Stock) is perpetual and has no expiration date. The Issuer has the option to redeem the Preferred Stock and the right to require the conversion of the Preferred Stock into shares of the common stock of the Issuer (the Common Stock), in each case, subject to specified conditions. |
| Common Stock Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 | Direct | 21,600 |
Reported balance
After 2026-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-18 · Grant · Acquired 21,600 · Balance 21,600 F1: This date is the date on which the reporting person subscribed to purchase the securities. The securities will be issued at a future date when the Issuer accepts the reporting person's subscription. F4: The reported securities are included within 10,800 Investor Units (the Units) purchased by the reporting person in the Regulation A offering of the Issuer for $5 per Unit. Each Unit consists of one share of Preferred Stock, each of which is initially convertible into two shares of Common Stock, and two warrants, each to purchase one share of Common Stock. F2: This security is convertible or exercisable, as applicable, at any time after issuance. F5: This security expires on the 36-month anniversary of the date of issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: This date is the date on which the reporting person subscribed to purchase the securities. The securities will be issued at a future date when the Issuer accepts the reporting person's subscription.
F2: This security is convertible or exercisable, as applicable, at any time after issuance.
F3: The Series A Convertible Preferred Stock (the Preferred Stock) is perpetual and has no expiration date. The Issuer has the option to redeem the Preferred Stock and the right to require the conversion of the Preferred Stock into shares of the common stock of the Issuer (the Common Stock), in each case, subject to specified conditions.
F4: The reported securities are included within 10,800 Investor Units (the Units) purchased by the reporting person in the Regulation A offering of the Issuer for $5 per Unit. Each Unit consists of one share of Preferred Stock, each of which is initially convertible into two shares of Common Stock, and two warrants, each to purchase one share of Common Stock.
F5: This security expires on the 36-month anniversary of the date of issuance.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2033-05-23 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 121,968 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-26-036378 · form4.xml · derivative · entry 5 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001140361-26-036378 · form4.xml · derivative · entry 4 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2035-06-26 F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $1.34 | Not disclosed |
DisclosureSEC source: 0001140361-26-036378 · form4.xml · derivative · entry 3 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2034-06-13 F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001140361-26-036378 · form4.xml · derivative · entry 2 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2033-05-23 F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $3.84 | Not disclosed |
DisclosureSEC source: 0001140361-26-036378 · form4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2032-05-25 F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantStock Option · Derivative | 121,968 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001140361-26-024520 · form4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,968 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:01 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantCommon Stock Warrant (right to buy) · Derivative | 21,600 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001199102-26-000004 · wk-form4_1771621308.xml · derivative · entry 2 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,600 Underlying: Common stock · 21,600 shares Expires not disclosed F1 · date: This date is the date on which the reporting person subscribed to purchase the securities. The securities will be issued at a future date when the Issuer accepts the reporting person's subscription. F4 · price: The reported securities are included within 10,800 Investor Units (the Units) purchased by the reporting person in the Regulation A offering of the Issuer for $5 per Unit. Each Unit consists of one share of Preferred Stock, each of which is initially convertible into two shares of Common Stock, and two warrants, each to purchase one share of Common Stock. F2 · derivative.exercise_date: This security is convertible or exercisable, as applicable, at any time after issuance. F5 · derivative.expiration_date: This security expires on the 36-month anniversary of the date of issuance. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:01 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantSeries A Convertible Preferred Stock · Derivative | 10,800 | Not disclosed Strike: $2.50 | Not disclosed |
DisclosureSEC source: 0001199102-26-000004 · wk-form4_1771621308.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,800 Underlying: Common stock · 21,600 shares Expires not disclosed F1 · date: This date is the date on which the reporting person subscribed to purchase the securities. The securities will be issued at a future date when the Issuer accepts the reporting person's subscription. F4 · price: The reported securities are included within 10,800 Investor Units (the Units) purchased by the reporting person in the Regulation A offering of the Issuer for $5 per Unit. Each Unit consists of one share of Preferred Stock, each of which is initially convertible into two shares of Common Stock, and two warrants, each to purchase one share of Common Stock. F2 · derivative.exercise_date: This security is convertible or exercisable, as applicable, at any time after issuance. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock (the Preferred Stock) is perpetual and has no expiration date. The Issuer has the option to redeem the Preferred Stock and the right to require the conversion of the Preferred Stock into shares of the common stock of the Issuer (the Common Stock), in each case, subject to specified conditions. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:06 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 172,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001199102-26-000002 · wk-form4_1770066405.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,000 Underlying: Common stock · 172,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 21:31 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 103,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001140361-25-024021 · form4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Shares · 103,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 22:31 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 107,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001401914-25-000004 · wk-form4_1738362699.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,000 Underlying: Common stock · 107,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 103,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001140361-24-030204 · form4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Shares · 103,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 13, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:34 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001401914-24-000006 · wk-form4_1710448428.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common stock · 750,000 shares Expires 2034-03-12 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:24 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-23-024253 · ownership.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or May 16, 2024. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:07 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001401914-23-000008 · wf-form4_167476720939649.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common stock · 750,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 21:46 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0000899243-22-019963 · doc4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or May 25, 2023. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 22:49 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,430 | $1.46 | $3,547.80 |
DisclosureSEC source: 0001209191-22-021847 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,642 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/21 Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 21:04 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 628,400 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001401914-22-000008 · wf-form4_164340383866492.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,400 Underlying: Common stock · 628,400 shares Expires 2032-01-25 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 22:19 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,430 | $1.86 | $4,519.80 |
DisclosureSEC source: 0001209191-22-000263 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,072 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/21 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:41 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,430 | $3.86 | $9,379.80 |
DisclosureSEC source: 0001209191-21-058476 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,502 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/21 Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:30 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 128,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0000899243-21-035679 · doc4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Shares · 128,000 shares Expires 2031-09-10 F1 · derivative.exercise_date: The stock option shall vest with respect to a third of the underlying common shares on June 17, 2022 and in 24 substantially equal monthly installments thereafter until June 17, 2024. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 20:21 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,430 | $4.91 | $11,931.30 |
DisclosureSEC source: 0001209191-21-044382 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,932 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/21 Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:35 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantCommon Stock | 24,295 | $2.06 | $50,047.70 |
DisclosureSEC source: 0001209191-21-024734 · doc4.xml · nonDerivative · entry 2 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,362 F2 · shares: The RSU's vests in four equal quarterly installments on 6/30/21, 9/30/21, 12/31/21 and 3/31/22. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:35 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,575 | $2.03 | $5,227.25 |
DisclosureSEC source: 0001209191-21-024734 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,067 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/3/20 Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:05 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 525,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001199102-21-000005 · wf-form4_161186790314013.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common stock · 525,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 21:09 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,575 | $2.47 | $6,360.25 |
DisclosureSEC source: 0001209191-21-000243 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,642 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/3/20 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 17:55 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,389 | $1.35 | $3,225.15 |
DisclosureSEC source: 0001209191-20-052568 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,217 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/3/20 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 19:11 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 2,389 | $2.03 | $4,849.67 |
DisclosureSEC source: 0001209191-20-040140 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,677 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/3/20 Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 19:21 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantCommon Stock | 23,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023741 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,066 F1 · shares: The RSU's vests in four equal quarterly installments on 6/30/2020, 9/30/2020, 12/31/2020 and 3/31/2021. Read SEC document |
| April 03, 2020 Filed Sep 17, 2020 16:59 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantCommon Stock | 929 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050822 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,606 F1 · shares: The RSU was granted on 4/3/20, but was contingent on stockholder approval of the Issuer's 2020 Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 9/15/20, and therefore for purposes of Section 16, the RSU was not "acquired" until such stockholder approval was obtained. The RSU's vest in two equal installments on 12/31/2020 and 3/31/2021. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 19:21 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 244 | $1.52 | $370.88 |
DisclosureSEC source: 0001209191-20-022460 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,173 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/19 Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:43 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001401914-20-000034 · wf-form4_158379021939186.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chef Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common stock · 280,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 23:47 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 246 | $0.84 | $207.60 |
DisclosureSEC source: 0001209191-20-000440 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,417 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/19 F2 · balance_after: The end of period holdings reflect a 1-15 reverse stock split effected by the Issuer on October 14, 2019. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:52 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 3,684 | $0.24 | $865.74 |
DisclosureSEC source: 0001209191-19-051880 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,944 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/19 Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:17 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 3,684 | $0.37 | $1,363.08 |
DisclosureSEC source: 0001209191-19-040462 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,628 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU dated 4/1/19 F2 · balance_after: Includes RSU's that were originally reported in Table II of the Reporting Person's Form 4 filed 4/3/19. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:21 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantRestricted Stock Units (RSU) · Derivative | 36,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023056 · doc4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,842 Underlying: Common Stock · 36,842 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · derivative.exercise_date: The RSU's vests in four equal quarterly installments on 6/30/19, 9/30/19, 12/31/19 and 3/31/20. F2 · derivative.expiration_date: The RSU's vests in four equal quarterly installments on 6/30/19, 9/30/19, 12/31/19 and 3/31/20. Read SEC document |
| March 31, 2019 Filed May 14, 2019 22:31 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 3,573 | $0.95 | $3,394.35 |
DisclosureSEC source: 0001209191-19-029772 · doc5.xml · nonDerivative · entry 3 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,470 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU granted 6/14/18 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:30 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001209191-19-006215 · doc4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| December 31, 2018 Filed May 14, 2019 22:31 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 3,573 | $1.30 | $4,644.90 |
DisclosureSEC source: 0001209191-19-029772 · doc5.xml · nonDerivative · entry 2 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,043 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU granted 6/14/18 Read SEC document |
| September 30, 2018 Filed May 14, 2019 22:31 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 3,573 | $1.18 | $4,216.14 |
DisclosureSEC source: 0001209191-19-029772 · doc5.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,616 F1 · acquired: Reporting the tax withholding of shares upon vesting of the RSU granted 6/14/18 Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 22:22 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 192,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001209191-18-050350 · doc4.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2028-09-07 F1 · derivative.exercise_date: This stock options vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| June 19, 2018 Filed Aug 1, 2018 01:15 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantRestricted Stock Units · Derivative | 26,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-002082 · ownership.xml · derivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,449 Underlying: Common Stock · 26,799 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: 40,650 restricted stock units vested on 3/31/2018. 26,799 restricted stock units to vest ratably on 9/30/18, 12/31/18 and 3/31/19. F2 · derivative.expiration_date: 40,650 restricted stock units vested on 3/31/2018. 26,799 restricted stock units to vest ratably on 9/30/18, 12/31/18 and 3/31/19. Read SEC document |
| June 14, 2018 Filed May 14, 2019 22:27 UTC Amendment | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantCommon Stock | 26,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029766 · doc4a.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,189 F1 · acquired: This amendment is being filed to correct the grant date of the 26,799 share RSU. The RSU was originally reported in Table II of the Reporting Person's Form 4 filed 7/31/2018. Read SEC document |
| March 31, 2018 Filed May 14, 2019 22:42 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | Tax withholdingCommon Stock | 16,260 | $1.19 | $19,349.40 |
DisclosureSEC source: 0001209191-19-029782 · doc4.xml · nonDerivative · entry 2 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,390 Read SEC document |
| February 06, 2018 Filed May 14, 2019 22:42 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantCommon Stock | 40,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029782 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,650 F1 · acquired: RSU was originally reported in Table II of the Reporting Person's Form 3 filed 02/22/2018 which has been amended to remove such award and is being reported herein. Read SEC document |
| July 19, 2017 Filed Jul 25, 2017 20:20 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantCommon Stock | 962,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-046159 · doc4.xml · nonDerivative · entry 1 JOHNSON SABRINA MARTUCCI · CIK 0001199102 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vincent S. Johnson and Sabrina M. Johnson Family Trust Dated February 4, 2005 Disclosed balance after: 962,062 F1 · price: In exchange for the issuance of shares of common stock and options to purchase shares of common stock of Dare Bioscience, Inc. (the "Corporation"), the Corporation acquired all of the issued and outstanding shares of common stock of Dare Bioscience Operations, Inc. ("Dare Operations") pursuant to the terms of a Stock Purchase Agreement, dated March 19, 2017, by and between the Corporation, Dare Operations and certain equityholders of Dare Operations party thereto, as filed with the Securities and Exchange Commission on Form 8-K on March 20, 2017 (such exchanges and issuances, the "Transaction"). F2 · price: The shares of common stock of the Corporation reported reflect the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017. These shares of common stock of the Corporation were received in connection with the Transaction in exchange for 4,739,295 shares of Dare Operations common stock. On the effective date of the Transaction, the closing price of the common stock of the Corporation, as reported on The Nasdaq Capital Market, was $6.56 per share (on a post-split basis). Each share of common stock of Dare Operations was cancelled and exchanged for the right to receive 0.2029969047 shares of common stock of the Corporation (on a post-split basis). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.